This company has been marked as potentially delisted and may not be actively trading. NASDAQ:CLBS Caladrius Biosciences (CLBS) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Caladrius Biosciences Stock (NASDAQ:CLBS) Get Caladrius Biosciences alerts:Sign Up Key Stats Today's Range N/A50-Day Range$0.43▼$8.3852-Week Range N/AVolume466,373 shsAverage Volume522,308 shsMarket Capitalization$26.05 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey. Read More Receive CLBS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Caladrius Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CLBS Stock News HeadlinesHARBOUR BIOMED LAUNCHES NONA BIOSCIENCES' "IDEAS TO IND" PRECLINICAL SOLUTIONS BUSINESS TO ACCELERATE GLOBAL BIOTHERAPEUTIC INNOVATIONNovember 30, 2022 | finance.yahoo.comCaladrius Biosciences, Inc.: Caladrius Biosciences and Cend Therapeutics Announce Closing of Merger and the Emergence of Lisata TherapeuticsSeptember 16, 2022 | finanznachrichten.deShots officially fired…Elon Musk just declared war on the wireless giants with a $17 billion spectrum deal that gives SpaceX the rights to deliver direct-to-cell service nationwide — a move tech analyst Jeff Brown says could shape the backbone of the coming space economy and create fortunes on a scale not seen since the rise of NVIDIA.October 16 at 2:00 AM | Brownstone Research (Ad)Caladrius Biosciences, Inc.: Caladrius Biosciences Announces Approval of Merger and Name Change to Lisata TherapeuticsSeptember 15, 2022 | finanznachrichten.deCaladrius Biosciences and Cend Therapeutics Announce Closing of Merger and the Emergence of Lisata TherapeuticsSeptember 15, 2022 | finance.yahoo.comCLBS Caladrius Biosciences, Inc.September 14, 2022 | seekingalpha.comCaladrius Biosciences Announces Approval of Merger and Name Change to Lisata TherapeuticsSeptember 14, 2022 | finance.yahoo.comHow to get the Protea Caladrius collection in Warframe: VeilbreakerSeptember 8, 2022 | msn.comSee More Headlines CLBS Stock Analysis - Frequently Asked Questions How were Caladrius Biosciences' earnings last quarter? Caladrius Biosciences, Inc. (NASDAQ:CLBS) released its quarterly earnings results on Thursday, November, 4th. The biotechnology company reported ($1.80) EPS for the quarter, beating the consensus estimate of ($1.95) by $0.15. When did Caladrius Biosciences' stock split? Caladrius Biosciences shares reverse split on the morning of Thursday, September 15th 2022.The 1-15 reverse split was announced on Thursday, September 15th 2022. The number of shares owned by shareholders was adjusted after the market closes on Thursday, September 15th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What other stocks do shareholders of Caladrius Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Caladrius Biosciences investors own include Meta Platforms (META), Brainstorm Cell Therapeutics (BCLI), HubSpot (HUBS), Alphabet (GOOG), NVIDIA (NVDA), OPKO Health (OPK) and Sorrento Therapeutics (SRNE). Company Calendar Last Earnings11/04/2021Today10/16/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Miscellaneous Health & Allied Services Sub-IndustryN/A Current SymbolNASDAQ:CLBS CIK320017 Webwww.caladrius.com Phone(908) 842-0100Fax646-514-7787Employees27Year Founded2006Profitability EPS (Trailing Twelve Months)($0.41) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$27.47 million Net MarginsN/A Pretax MarginN/A Return on Equity-27.24% Return on Assets-26.08% Debt Debt-to-Equity RatioN/A Current Ratio22.33 Quick Ratio22.33 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.54 per share Price / BookN/AMiscellaneous Outstanding Shares60,583,000Free Float59,250,000Market Cap$26.05 million OptionableOptionable Beta0.91 Social Links These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:CLBS) was last updated on 10/16/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredBuilding The Infrastructure for the Coming Financial ResetWhile China pushes nearly $1 trillion through its new digital currency, one emerging company is quietly buildi...Intellistake | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredTrump Devises the Death of the IRS ☠️Trump has just signed an executive order creating America's first-ever National Investment Fund — a game-chang...Angel Publishing | SponsoredShots officially fired…Elon Musk just declared war on the wireless giants with a $17 billion spectrum deal that gives SpaceX the righ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Caladrius Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Caladrius Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
